Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 14, 2019

GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome

GlaxoSmithKline (GSK) said that its respiratory drug Nucala (mepolizumab) has succeeded in reducing flares in patients with hypereosinophilic syndrome (HES) in a phase 3 study.

GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome